About Steve

Steven M. Przesmicki specializes in corporate and securities law, and regularly acts as outside corporate counsel to public and private companies. Steve represent clients on SEC and corporate governance matters, public financings, mergers and acquisitions, IPOs, and venture capital and other private financings. He has represented issuers and underwriters in offerings involving well over $2 billion of securities, and advised clients on M&A transactions ranging in value from under $10 million to up to several billion dollars. Steve has also represented clients in a number of other complex transactions such as debt redemptions, joint ventures, option-exchange tender offers and strategic commercial transactions.

View full bio

Experience

InnoCare Pharma and Zenas BioPharma Announce License Agreement

InnoCare Pharma and Zenas BioPharma Announce License Agreement

October 8, 2025

Cooley advised InnoCare Pharma, a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing first-in-class and best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide, on its transformational license agreement with Zenas BioPharma, granting Zenas global development and commercialization rights to orelabrutinib for multiple sclerosis and across all therapeutic areas other than oncology.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Freddy Yip
Associate, Hong Kong
Peter Adams
Partner, San Diego
Aaron Pomeroy
Partner, Colorado
Steve Przesmicki
Partner, San Diego
Julia R. Brinton
Special Counsel, Washington, DC
David Burns
Special Counsel, Washington, DC
Sharon Connaughton
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Michael Shen
Special Counsel, Shanghai
Robert Eisenbach
Of Counsel, San Francisco
Rachel Thorn
Of counsel, New York
Jameson Davis
Associate, Boston
Amanda Pacheco
Associate, Palo Alto
Ivy Wang
Associate, Shanghai
Denny Xu
Associate, Boston
Zhijing Yu
Associate, Singapore

Related Practices & Industries

Life Sciences Corporate Partnering and Licensing
Emerging Companies
Antitrust and Competition
Capital Markets
Cyber/Data/Privacy
Tax
Securities Litigation + Enforcement
Business Restructuring
Commercial Litigation
Healthcare

Hengrui Pharma and Braveheart Bio Enter Into Exclusive License Agreement

Hengrui Pharma and Braveheart Bio Enter Into Exclusive License Agreement

September 5, 2025

Cooley advised Hengrui Pharma, a global pharmaceutical company, on its exclusive license agreement with Braveheart Bio for HRS-1893, a small-molecule inhibitor of cardiac myosin independently developed by Hengrui Pharma with best-in-class potential.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Freddy Yip
Associate, Hong Kong
Steve Przesmicki
Partner, San Diego
Navya Dasari
Associate, New York
Max Levinbook
Associate, San Diego
Jeffrey J. Tolin
Partner, New York
Amanda Pacheco
Associate, Palo Alto
David Burns
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Zhijing Yu
Associate, Singapore
Christopher Kimball
Partner, Washington, DC
Robert Eisenbach
Of Counsel, San Francisco
Rachel Thorn
Of counsel, New York
Karen Tsai
Special Counsel, Washington, DC

Related Practices & Industries

Life Sciences Corporate Partnering and Licensing
Life Sciences
Healthcare
Biotechnology
Tax
Antitrust and Competition
Cyber/Data/Privacy
CFIUS
Business Restructuring
Commercial Litigation
Asia

Dynavax Announces Successful Proxy Contest

Dynavax Announces Successful Proxy Contest

June 11, 2025

Cooley advised Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, on its successful proxy contest against Deep Track Capital.

Read more

Related contacts

Bill Roegge
Partner, New York
Steve Przesmicki
Partner, San Diego
Barbara Borden
Senior Counsel, San Diego
Julia Kim
Special Counsel, New York
Patrick Reed
Associate, Palo Alto
Matthew Choy
Associate, New York
Sarah Lightdale
Partner, New York
Brian P. Golger
Associate, New York
Marina Remennik
Special Counsel, Palo Alto
Andrew Mettry
Associate
Michelle Peleg
Associate, San Francisco
Irene Sun
Associate, Palo Alto

Related Practices & Industries

Activism Defense
Capital Markets
Compensation and Benefits
Emerging Companies
Mergers and Acquisitions
Commercial Litigation
Life Sciences

Sirius Therapeutics Announces Collaboration With CRISPR Therapeutics

Sirius Therapeutics Announces Collaboration With CRISPR Therapeutics

May 19, 2025

Cooley advised Sirius Therapeutics, a clinical-stage biotech company developing innovative small interfering RNA (siRNA) therapies for global markets, on its strategic partnership to develop and commercialize siRNA therapies with CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Jiqiang Lin
Associate, New York
Navya Dasari
Associate, New York
Aaron Pomeroy
Partner, Colorado
Todd Gluth
Partner, San Diego
Rick Jantz
Associate, Santa Monica
Steve Przesmicki
Partner, San Diego
Robert Eisenbach
Of Counsel, San Francisco
Rachel Thorn
Of counsel, New York
David Burns
Special Counsel, Washington, DC
Eileen Marshall
Partner, Washington, DC
Jonathan Rivinus
Partner, Colorado

Related Practices & Industries

Life Sciences Corporate Partnering and Licensing
Life Sciences
Healthcare
Biotechnology
Tax
Capital Markets
Business Restructuring
Commercial Litigation
Antitrust and Competition

Jiangsu Hengrui Pharmaceuticals Announces License Agreement With Merck

Jiangsu Hengrui Pharmaceuticals Announces License Agreement With Merck

March 25, 2025

Cooley advised Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma), a global pharmaceutical company focused on scientific and technological innovation, on its exclusive license agreement with Merck (NYSE: MRK), known as MSD outside of the US and Canada, for HRS-5346, an investigational oral small molecule lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a phase 2 clinical trial in China.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Jiqiang Lin
Associate, New York
Andrew Epstein
Special Counsel, Seattle
Zhijing Yu
Associate, Singapore
David Burns
Special Counsel, Washington, DC
Julia R. Brinton
Special Counsel, Washington, DC
Navya Dasari
Associate, New York
Amanda Pacheco
Associate, Palo Alto
Robert Eisenbach
Of Counsel, San Francisco
Russell Anderson
Partner, London
Megan Browdie
Partner, Washington, DC
Steve Przesmicki
Partner, San Diego

Related Practices & Industries

Life Sciences Corporate Partnering and Licensing
Life Sciences
Healthcare
Patent Counseling and Prosecution
Cyber/Data/Privacy
Antitrust and Competition
Tax
Business Restructuring
Mergers and Acquisitions
Capital Markets
Asia
View more

Admissions and credentials

California

Wisconsin

Rankings and accolades

Best Lawyers in America: Corporate Law

San Diego Super Lawyers

Southern California Super Lawyers

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.